MRNA
$196.48+4.81%
as of close, Oct 7, 2026
☾ AH $196.48 +4.81%
Moderna Inc.Stock · HealthcareS&P 500 Equal Weight 0.2%Nasdaq Composite 0.04%S&P 500 0.04%Russell 1000 0.04%Russell 3000 0.04%US Stock Market 0.03%
MRNA SEC filings (2026)
CIK 1682852 · Biological Products, (No Diagnostic Substances) (SIC 2836) · incorporated in DE · fiscal year ends in December
1,493 filings on EDGAR since 2016 · 9 annual, 23 quarterly, 117 current · financial statements · earnings
Latest 10-K
Feb 20, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Jul 31, 2026
quarter to Jun 30, 2026
Latest 8-K
Sep 30, 2026
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Last earnings release
Jul 31, 2026
−$1.97 vs −$1.97 · ▼ 5.4%
Filings on file
1,493
since 2016, 1,225 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
- Sep 308-K8-K · Moderna Adds Chief Operating Officer Role as Company Expands into OncologyDirectors or officers; compensation; Regulation FD disclosure
- Sep 15Insider saleHoge Stephen (President) sold 40,281 shares for $5.9M at $146.07 under a 10b5-1 plan
- Sep 14Insider saleHoge Stephen (President) sold 40,294 shares for $5.8M at $144.13 under a 10b5-1 plan
- Sep 10Insider saleMock James M (Chief Financial Officer) sold 34,836 shares for $4.7M at $134.49 under a 10b5-1 plan
- Sep 1Insider saleKlinger Shannon Thyme (Chief Legal Officer) sold 3,471 shares for $486K at $139.95 under a 10b5-1 plan
- Sep 18-K8-K · Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior NotesMaterial definitive agreement; New financial obligation; Unregistered sale of equity; Other events
August 2026
July 2026
- Jul 31EarningsEarnings release — EPS −$1.97 vs −$1.97 est. (+0.0%); revenue $145.0M (+2% y/y) 5.4%
- Jul 31ReportQuarterly report, Q2 2026 — revenue $145.0M (+2% y/y), net income −$782.0M, EPS −$1.97
- Jul 15Insider saleHoge Stephen (President) sold 53,336 shares for $3.6M at $67.60 under a 10b5-1 plan
- Jul 88-K8-K · Moderna Appoints Michael McDonnell to Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure
June 2026
May 2026
- May 21Insider saleAFEYAN NOUBAR (Director) sold 9,263 shares for $434K at $46.84
- May 15Insider saleHoge Stephen (President) sold 53,336 shares for $2.6M at $48.40 under a 10b5-1 plan
- May 118-K8-K · Charter, bylaws or fiscal-year change; Shareholder vote results
- May 1EarningsEarnings release — EPS −$1.18 vs −$3.02 est. (+60.9%); revenue $389.0M (+260% y/y) 1.2%
- May 1ReportQuarterly report, Q1 2026 — revenue $389.0M (+260% y/y), net income −$1.34B, EPS −$3.40
- May 1Insider saleHussain Abbas (Director) sold 5,682 shares for $265K at $46.63 under a 10b5-1 plan
March 2026
- Mar 16ProxyProxy · Additional proxy materials
- Mar 16ProxyProxy · Proxy statement
- Mar 16ProxyProxy · Annual report to shareholders
- Mar 58-K8-K · Material definitive agreement
- Mar 2Insider saleKlinger Shannon Thyme (Chief Legal Officer) sold 13,885 shares for $726K at $52.29 under a 10b5-1 plan
February 2026
- Feb 23Insider saleHoge Stephen (President) sold 160,009 shares for $7.8M at $48.84 under a 10b5-1 plan
- Feb 20ReportAnnual report, FY2025 — revenue $1.94B (−40% y/y), net income −$2.82B, EPS −$7.26
- Feb 13EarningsEarnings release — EPS −$2.11 vs −$2.60 est. (+18.9%); revenue $678.0M (−30% y/y) 5.3%
- Feb 118-K8-K · Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010Regulation FD disclosure; Other events
January 2026
- Jan 128-K8-K · Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare ConferenceResults of operations; Regulation FD disclosure
- Jan 58-K8-K · Regulation FD disclosure
November 2025
- Nov 248-K8-K · Material definitive agreement; New financial obligation
- Nov 208-K8-K · Moderna Analyst Day Highlights Pipeline Progress and Business Strategy UpdatesRegulation FD disclosure
- Nov 138-K8-K · Shareholder vote results
- Nov 6EarningsEarnings release — EPS −$0.51 vs −$2.15 est. (+76.3%); revenue $1.02B (−45% y/y) 3.3%
- Nov 6ReportQuarterly report, Q3 2025 — revenue $1.02B (−45% y/y), net income −$200.0M, EPS −$0.51
October 2025
- Oct 20ProxyProxy · Additional proxy materials
- Oct 15ProxyProxy · Proxy statement
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $63.9M in 13 sales and bought nothing on the open market; 159 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 15, 2026Form 4 | Hoge StephenPresidentSold · $5.9M · 40,281 sh · 10b5-1 |
| Sep 14, 2026Form 4 | Hoge StephenPresidentSold · $5.8M · 40,294 sh · 10b5-1 |
| Sep 10, 2026Form 4 | Mock James MChief Financial OfficerSold · $4.7M · 34,836 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerSold · $486K · 3,471 sh · 10b5-1 |
| Aug 5, 2026Form 4 | Bancel StephaneChief Executive Officer · DirectorSold · $28.7M · 499,246 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Hoge StephenPresidentSold · $3.6M · 53,336 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Hoge StephenPresidentSold · $2.7M · 53,336 sh · 10b5-1 |
| Jun 4, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerSold · $174K · 3,471 sh · 10b5-1 |
| May 21, 2026Form 4 | AFEYAN NOUBARDirectorSold · $434K · 9,263 sh |
| May 15, 2026Form 4 | Hoge StephenPresidentSold · $2.6M · 53,336 sh · 10b5-1 |
| May 1, 2026Form 4 | Hussain AbbasDirectorSold · $265K · 5,682 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerSold · $726K · 13,885 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Hoge StephenPresidentSold · $7.8M · 160,009 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 159 transactions
| Date | Insider |
|---|---|
| Oct 5, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $134K · 704 sh |
| Oct 5, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 1,454 sh |
| Oct 5, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 1,454 sh |
| Sep 15, 2026Form 4 | Hoge StephenPresidentExercise or conversion · $933K · 76,452 sh · 10b5-1 |
| Sep 15, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Stock Option (Right to Buy) · $0 · 76,452 sh · 10b5-1 |
| Sep 14, 2026Form 4 | Hoge StephenPresidentExercise or conversion · $933K · 76,453 sh · 10b5-1 |
| Sep 14, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Stock Option (Right to Buy) · $0 · 76,453 sh · 10b5-1 |
| Sep 10, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · $614K · 19,836 sh · 10b5-1 |
| Sep 10, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 19,836 sh · 10b5-1 |
| Sep 4, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $849K · 5,704 sh |
| Sep 4, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $849K · 5,704 sh |
| Sep 4, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · — · 11,797 sh |
| Sep 4, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 11,797 sh |
| Sep 4, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 11,797 sh |
| Sep 4, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 11,797 sh |
| Sep 1, 2026Form 4 | Hoge StephenPresidentTax withholding · $630K · 4,489 sh |
| Sep 1, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $168K · 1,197 sh |
| Sep 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $147K · 1,048 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · $107K+ · 5,637 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Hoge StephenPresidentExercise or conversion · — · 9,283 sh |
| Sep 1, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Restricted Stock Units · $0 · 9,283 sh |
| Sep 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 3,471 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 2,475 sh |
| Sep 1, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 2,475 sh |
| Sep 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 2,166 sh · 10b5-1 |
| Aug 28, 2026Form 4 | Hoge StephenPresidentTax withholding · $42K · 296 sh |
| Aug 28, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $23K · 160 sh |
| Aug 28, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $23K · 160 sh |
| Aug 28, 2026Form 4 | Hoge StephenPresidentExercise or conversion · — · 611 sh |
| Aug 28, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Restricted Stock Units · $0 · 611 sh |
| Aug 28, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 329 sh |
| Aug 28, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 329 sh |
| Aug 28, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · — · 329 sh |
| Aug 28, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 329 sh |
| Aug 27, 2026Form 4 | Hoge StephenPresidentTax withholding · $104K · 695 sh |
| Aug 27, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $56K · 375 sh |
| Aug 27, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $56K · 375 sh |
| Aug 27, 2026Form 4 | Hoge StephenPresidentExercise or conversion · — · 1,437 sh |
| Aug 27, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Restricted Stock Units · $0 · 1,437 sh |
| Aug 27, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 774 sh |
| Aug 27, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 774 sh |
| Aug 27, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · — · 774 sh |
| Aug 27, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 774 sh |
| Aug 6, 2026Form 4 | Bancel StephaneChief Executive Officer · DirectorExercise or conversion · $4.8M · 252,469 sh · 10b5-1 |
| Aug 6, 2026Form 4 | Bancel StephaneChief Executive Officer · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 252,469 sh · 10b5-1 |
| Aug 5, 2026Form 4 | Bancel StephaneChief Executive Officer · DirectorExercise or conversion · $9.6M · 499,246 sh · 10b5-1 |
| Aug 5, 2026Form 4 | Bancel StephaneChief Executive Officer · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 499,246 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Hoge StephenPresidentExercise or conversion · $1.0M · 53,336 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Stock Option (Right to Buy) · $0 · 53,336 sh · 10b5-1 |
| Jul 8, 2026Form 4 | McDonnell Michael R.DirectorAward · Stock Option (Right to Buy) · $0 · 7,415 sh |
| Jul 8, 2026Form 4 | McDonnell Michael R.DirectorAward · Restricted Stock Units · $0 · 7,351 sh |
| Jul 5, 2026Form 4 | Banque Soria EsterChief Commercial OfficerAward · Restricted Stock Units · $0 · 38,364 sh |
| Jul 5, 2026Form 4 | Banque Soria EsterChief Commercial OfficerAward · Stock Option (Right to Buy) · $0 · 18,658 sh |
| Jul 2, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $51K · 703 sh |
| Jul 2, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 1,452 sh |
| Jul 2, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 1,452 sh |
| Jun 15, 2026Form 4 | Hoge StephenPresidentExercise or conversion · $1.0M · 53,336 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Stock Option (Right to Buy) · $0 · 53,336 sh · 10b5-1 |
| Jun 5, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $294K · 5,705 sh |
| Jun 5, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $294K · 5,705 sh · 10b5-1 |
| Jun 5, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 11,798 sh |
| Jun 5, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 11,798 sh |
| Jun 5, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · — · 11,798 sh · 10b5-1 |
| Jun 5, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 11,798 sh · 10b5-1 |
| Jun 4, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · $107K · 3,471 sh · 10b5-1 |
| Jun 4, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 3,471 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Hoge StephenPresidentTax withholding · $212K · 4,488 sh |
| Jun 1, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $56K · 1,197 sh |
| Jun 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $49K · 1,047 sh |
| Jun 1, 2026Form 4 | Hoge StephenPresidentExercise or conversion · — · 9,282 sh |
| Jun 1, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Restricted Stock Units · $0 · 9,282 sh |
| Jun 1, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 2,475 sh |
| Jun 1, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 2,475 sh |
| Jun 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · — · 2,165 sh |
| Jun 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 2,165 sh |
| May 28, 2026Form 4 | Hoge StephenPresidentTax withholding · $14K · 295 sh |
| May 28, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $7,570 · 159 sh |
| May 28, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $7,570 · 159 sh |
| May 28, 2026Form 4 | Hoge StephenPresidentExercise or conversion · — · 610 sh |
| May 28, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Restricted Stock Units · $0 · 610 sh |
| May 28, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · — · 328 sh |
| May 28, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 328 sh |
| May 28, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 328 sh |
| May 28, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 328 sh |
| May 27, 2026Form 4 | Hoge StephenPresidentTax withholding · $33K · 695 sh |
| May 27, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $18K · 374 sh |
| May 27, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $18K · 374 sh |
| May 27, 2026Form 4 | Hoge StephenPresidentExercise or conversion · — · 1,437 sh |
| May 27, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Restricted Stock Units · $0 · 1,437 sh |
| May 27, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · — · 773 sh |
| May 27, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 773 sh |
| May 27, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 773 sh |
| May 27, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 773 sh |
| May 21, 2026Form 4 | AFEYAN NOUBARDirectorExercise or conversion · $177K · 9,263 sh |
| May 21, 2026Form 4 | AFEYAN NOUBARDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 9,263 sh |
| May 15, 2026Form 4 | Hoge StephenPresidentExercise or conversion · $1.0M · 53,336 sh · 10b5-1 |
| May 15, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Stock Option (Right to Buy) · $0 · 53,336 sh · 10b5-1 |
| May 6, 2026Form 4 | AFEYAN NOUBARDirectorAward · Stock Option (Right to Buy) · $0 · 12,908 sh |
| May 6, 2026Form 4 | Horning SandraDirectorAward · Stock Option (Right to Buy) · $0 · 9,681 sh |
| May 6, 2026Form 4 | Rubenstein David M.DirectorAward · Stock Option (Right to Buy) · $0 · 9,681 sh |
| May 6, 2026Form 4 | Tallett Elizabeth EDirectorAward · Restricted Stock Units · $0 · 8,371 sh |
| May 6, 2026Form 4 | NABEL ELIZABETH GDirectorAward · Restricted Stock Units · $0 · 8,371 sh |
| May 6, 2026Form 4 | Hussain AbbasDirectorAward · Restricted Stock Units · $0 · 8,371 sh |
| May 6, 2026Form 4 | Nader FrancoisDirectorAward · Stock Option (Right to Buy) · $0 · 6,454 sh |
| May 6, 2026Form 4 | Nader FrancoisDirectorAward · Restricted Stock Units · $0 · 4,185 sh |
| May 6, 2026Form 4 | Horning SandraDirectorAward · Restricted Stock Units · $0 · 2,092 sh |
| May 6, 2026Form 4 | Rubenstein David M.DirectorAward · Restricted Stock Units · $0 · 2,092 sh |
| Apr 30, 2026Form 4 | NABEL ELIZABETH GDirectorExercise or conversion · — · 16,233 sh |
| Apr 30, 2026Form 4 | NABEL ELIZABETH GDirectorExercise or conversion · Restricted Stock Units · $0 · 16,233 sh |
| Apr 30, 2026Form 4 | Hussain AbbasDirectorExercise or conversion · — · 16,233 sh · 10b5-1 |
| Apr 30, 2026Form 4 | Hussain AbbasDirectorExercise or conversion · Restricted Stock Units · $0 · 16,233 sh · 10b5-1 |
| Apr 30, 2026Form 4 | Horning SandraDirectorExercise or conversion · — · 16,233 sh |
| Apr 30, 2026Form 4 | Horning SandraDirectorExercise or conversion · Restricted Stock Units · $0 · 16,233 sh |
| Apr 30, 2026Form 4 | Nader FrancoisDirectorExercise or conversion · — · 12,174 sh |
| Apr 30, 2026Form 4 | Nader FrancoisDirectorExercise or conversion · Restricted Stock Units · $0 · 12,174 sh |
| Apr 30, 2026Form 4 | Rubenstein David M.DirectorExercise or conversion · — · 8,116 sh |
| Apr 30, 2026Form 4 | Rubenstein David M.DirectorExercise or conversion · Restricted Stock Units · $0 · 8,116 sh |
| Apr 30, 2026Form 4 | Tallett Elizabeth EDirectorExercise or conversion · — · 4,058 sh |
| Apr 30, 2026Form 4 | Tallett Elizabeth EDirectorExercise or conversion · Restricted Stock Units · $0 · 4,058 sh |
| Apr 2, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $35K · 703 sh |
| Apr 2, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 1,453 sh |
| Apr 2, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 1,453 sh |
| Mar 5, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $330K · 5,704 sh |
| Mar 5, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $330K · 5,704 sh |
| Mar 5, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 11,797 sh |
| Mar 5, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 11,797 sh |
| Mar 5, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · — · 11,797 sh |
| Mar 5, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 11,797 sh |
| Mar 2, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · $430K · 13,885 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Stock Option (Right to Buy) · $0 · 13,885 sh · 10b5-1 |
| Mar 1, 2026Form 4 | Bancel StephaneChief Executive Officer · DirectorAward · Stock Option (Right to Buy) · $0 · 250,932 sh |
| Mar 1, 2026Form 4 | Hoge StephenPresidentAward · Restricted Stock Units · $0 · 165,230 sh |
| Mar 1, 2026Form 4 | Hoge StephenPresidentAward · Stock Option (Right to Buy) · $0 · 125,466 sh |
| Mar 1, 2026Form 4 | Mock James MChief Financial OfficerAward · Restricted Stock Units · $0 · 49,569 sh |
| Mar 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerAward · Restricted Stock Units · $0 · 38,553 sh · 10b5-1 |
| Mar 1, 2026Form 4 | Mock James MChief Financial OfficerAward · Stock Option (Right to Buy) · $0 · 37,639 sh |
| Mar 1, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerAward · Stock Option (Right to Buy) · $0 · 29,275 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Hoge StephenPresidentTax withholding · $996K · 19,260 sh |
| Feb 27, 2026Form 4 | Mock James MChief Financial OfficerTax withholding · $275K · 5,323 sh |
| Feb 27, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerTax withholding · $250K · 4,837 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Hoge StephenPresidentExercise or conversion · — · 39,830 sh |
| Feb 27, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Restricted Stock Units · $0 · 39,830 sh |
| Feb 27, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · — · 11,004 sh |
| Feb 27, 2026Form 4 | Mock James MChief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 11,004 sh |
| Feb 27, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · — · 9,999 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Klinger Shannon ThymeChief Legal OfficerExercise or conversion · Restricted Stock Units · $0 · 9,999 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Hoge StephenPresidentExercise or conversion · $3.1M · 160,009 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Hoge StephenPresidentExercise or conversion · Stock Option (Right to Buy) · $0 · 160,009 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Bancel StephaneChief Executive Officer · DirectorTax withholding · $229K · 5,450 sh |
| Feb 11, 2026Form 4 | Hoge StephenPresidentTax withholding · $99K · 2,362 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 17 filings
| Filed | What it is |
|---|---|
| Sep 30, 20268-K | Moderna Adds Chief Operating Officer Role as Company Expands into OncologyDirectors or officers; compensation; Regulation FD disclosure |
| Sep 1, 20268-K | Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior NotesMaterial definitive agreement; New financial obligation; Unregistered sale of equity; Other events |
| Jul 31, 202610-Q | Quarterly report, Q2 2026 — revenue $145.0M (+2% y/y), net income −$782.0M, EPS −$1.97 |
| Jul 31, 20268-K | Earnings release — EPS −$1.97 vs −$1.97 est. (+0.0%); revenue $145.0M (+2% y/y) 5.4% |
| Jul 8, 20268-K | Moderna Appoints Michael McDonnell to Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure |
| May 11, 20268-K | Charter, bylaws or fiscal-year change; Shareholder vote results |
| May 1, 202610-Q | Quarterly report, Q1 2026 — revenue $389.0M (+260% y/y), net income −$1.34B, EPS −$3.40 |
| May 1, 20268-K | Earnings release — EPS −$1.18 vs −$3.02 est. (+60.9%); revenue $389.0M (+260% y/y) 1.2% |
| Mar 16, 2026DEFA14A | Additional proxy materials |
| Mar 16, 2026DEF 14A | Proxy statement |
| Mar 16, 2026ARS | Annual report to shareholders |
| Mar 5, 20268-K | Material definitive agreement |
| Feb 20, 202610-K | Annual report, FY2025 — revenue $1.94B (−40% y/y), net income −$2.82B, EPS −$7.26 |
| Feb 13, 20268-K | Earnings release — EPS −$2.11 vs −$2.60 est. (+18.9%); revenue $678.0M (−30% y/y) 5.3% |
| Feb 11, 20268-K | Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010Regulation FD disclosure; Other events |
| Jan 12, 20268-K | Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare ConferenceResults of operations; Regulation FD disclosure |
| Jan 5, 20268-K | Regulation FD disclosure |
2025 · 19 filings
| Filed | What it is |
|---|---|
| Nov 24, 20258-K | Material definitive agreement; New financial obligation |
| Nov 20, 20258-K | Moderna Analyst Day Highlights Pipeline Progress and Business Strategy UpdatesRegulation FD disclosure |
| Nov 13, 20258-K | Shareholder vote results |
| Nov 6, 202510-Q | Quarterly report, Q3 2025 — revenue $1.02B (−45% y/y), net income −$200.0M, EPS −$0.51 |
| Nov 6, 20258-K | Earnings release — EPS −$0.51 vs −$2.15 est. (+76.3%); revenue $1.02B (−45% y/y) 3.3% |
| Oct 20, 2025DEFA14A | Additional proxy materials |
| Oct 15, 2025DEF 14A | Proxy statement |
| Oct 3, 2025PRE 14A | Preliminary proxy statement |
| Aug 1, 202510-Q | Quarterly report, Q2 2025 — revenue $142.0M (−41% y/y), net income −$825.0M, EPS −$2.13 |
| Aug 1, 20258-K | Results of operations |
| May 5, 20258-K | Shareholder vote results |
| May 1, 202510-Q | Quarterly report, Q1 2025 — revenue $108.0M (−35% y/y), net income −$971.0M, EPS −$2.52 |
| May 1, 20258-K | Results of operations |
| Mar 11, 2025DEFA14A | Additional proxy materials |
| Mar 11, 2025DEF 14A | Proxy statement |
| Mar 11, 2025ARS | Annual report to shareholders |
| Feb 21, 202510-K | Annual report, FY2024 — revenue $3.24B (−53% y/y), net income −$3.56B, EPS −$9.28 |
| Feb 14, 20258-K | Results of operations |
| Jan 13, 20258-K | Results of operations; Regulation FD disclosure |
2024 · 17 filings
| Filed | What it is |
|---|---|
| Nov 7, 202410-Q | Quarterly report, Q3 2024 — revenue $1.86B (+2% y/y), net income $13.0M, EPS $0.03 |
| Nov 7, 20248-K | Results of operations |
| Oct 2, 20248-K | Directors or officers; compensation; Regulation FD disclosure |
| Sep 12, 20248-K | Regulation FD disclosure |
| Aug 1, 202410-Q | Quarterly report, Q2 2024 — revenue $241.0M (−30% y/y), net income −$1.28B, EPS −$3.33 |
| Aug 1, 20248-K | Results of operations |
| Jul 23, 20248-K | Directors or officers; compensation; Regulation FD disclosure |
| May 9, 20248-K | Charter, bylaws or fiscal-year change; Shareholder vote results |
| May 2, 202410-Q | Quarterly report, Q1 2024 — revenue $167.0M (−91% y/y), net income −$1.18B, EPS −$3.07 |
| May 2, 20248-K | Results of operations |
| Mar 21, 2024DEFA14A | Additional proxy materials |
| Mar 21, 2024DEF 14A | Proxy statement |
| Mar 15, 2024ARS | Annual report to shareholders |
| Mar 11, 2024PRE 14A | Preliminary proxy statement |
| Feb 23, 202410-K | Annual report, FY2023 — revenue $6.85B (−64% y/y), net income −$4.71B, EPS −$12.33 |
| Feb 22, 20248-K | Results of operations |
| Jan 8, 20248-K | Results of operations; Regulation FD disclosure |
2023 · 20 filings — 11 × 8-K, 3 × 10-Q, 2 × DEFA14A and 4 other forms
| Filed | What it is |
|---|---|
| Nov 3, 202310-Q | Quarterly report, Q3 2023 — revenue $1.83B (−46% y/y), net income −$3.63B, EPS −$9.53 |
| Aug 3, 202310-Q | Quarterly report, Q2 2023 — revenue $344.0M (−93% y/y), net income −$1.38B, EPS −$3.62 |
| May 4, 202310-Q | Quarterly report, Q1 2023 — revenue $1.86B (−69% y/y), net income $79.0M, EPS $0.19 |
| Apr 14, 2023DEFA14A | Additional proxy materials |
| Apr 13, 2023PX14A6G | Shareholder exempt solicitation |
| Mar 15, 2023DEFA14A | Additional proxy materials |
| Mar 15, 2023DEF 14A | Proxy statement |
| Feb 27, 2023ARS | Annual report to shareholders |
| Feb 24, 202310-K | Annual report, FY2022 — revenue $19.26B (+4% y/y), net income $8.36B, EPS $20.12 |
11 current reports (8-K) not listed; the year is on EDGAR.
2022 · 23 filings — 13 × 8-K, 3 × 10-Q, 2 × 8-K/A and 4 other forms
| Filed | What it is |
|---|---|
| Nov 3, 202210-Q | Quarterly report, Q3 2022 — revenue $3.36B (−32% y/y), net income $1.04B, EPS $2.53 |
| Aug 3, 202210-Q | Quarterly report, Q2 2022 — revenue $4.75B (+9% y/y), net income $2.20B, EPS $5.24 |
| May 4, 202210-Q | Quarterly report, Q1 2022 — revenue $6.07B (+213% y/y), net income $3.66B, EPS $8.58 |
| Mar 25, 2022PX14A6G | Shareholder exempt solicitation |
| Mar 21, 2022PX14A6G | Shareholder exempt solicitation |
| Mar 9, 2022DEFA14A | Additional proxy materials |
| Mar 9, 2022DEF 14A | Proxy statement |
| Feb 25, 202210-K | Annual report, FY2021 — revenue $18.47B (+2200% y/y), net income $12.20B, EPS $28.29 |
15 current reports (8-K) not listed; the year is on EDGAR.
2021 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 4, 202110-Q | Quarterly report, Q3 2021 — revenue $4.97B (+3065% y/y), net income $3.33B, EPS $7.70 |
| Aug 5, 202110-Q | Quarterly report, Q2 2021 — revenue $4.35B (+6399% y/y), net income $2.78B, EPS $6.46 |
| May 6, 202110-Q | Quarterly report, Q1 2021 — revenue $1.94B (+24113% y/y), net income $1.22B, EPS $2.84 |
| Mar 10, 2021DEFA14A | Additional proxy materials |
| Mar 10, 2021DEF 14A | Proxy statement |
| Feb 26, 202110-K | Annual report, FY2020 — revenue $803.0M (+1234% y/y), net income −$747.0M, EPS −$1.96 |
10 current reports (8-K) not listed; the year is on EDGAR.
2020 · 44 filings — 36 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
| Filed | What it is |
|---|---|
| Oct 30, 202010-Q | Quarterly report, Q3 2020 — revenue $157.0M (+821% y/y), net income −$233.0M, EPS −$0.59 |
| Aug 6, 202010-Q | Quarterly report, Q2 2020 — revenue $67.0M (+412% y/y), net income −$117.0M, EPS −$0.31 |
| May 7, 202010-Q | Quarterly report, Q1 2020 — revenue $8.0M (−50% y/y), net income −$124.0M, EPS −$0.35 |
| Apr 10, 2020DEFA14A | Additional proxy materials |
| Mar 16, 2020DEF 14A | Proxy statement |
| Feb 27, 202010-K | Annual report, FY2019 — revenue $60.2M (−55% y/y), net income −$514.0M, EPS −$1.55 |
| Feb 3, 2020DEFA14A | Additional proxy materials |
37 current reports (8-K) not listed; the year is on EDGAR.
2019 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 6, 201910-Q | Quarterly report, Q3 2019 — revenue $17.0M (−59% y/y), net income −$123.2M |
| Aug 8, 201910-Q | Quarterly report, Q2 2019 — revenue $13.1M (−55% y/y), net income −$134.9M |
| May 15, 2019DEF 14A | Proxy statement |
| May 9, 201910-Q | Quarterly report, Q1 2019 — revenue $16.0M (−45% y/y), net income −$132.6M |
| Apr 25, 201910-K/A | Annual report, amended |
| Mar 13, 201910-K | Annual report, FY2018 — revenue $135.1M (−34% y/y), net income −$384.7M |
14 current reports (8-K) not listed; the year is on EDGAR.
2018 · 1 filing — 1 × 8-K
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 80 filings — 53 × 4, 15 × 144, 5 × SCHEDULE 13G/A and 3 other forms
| Filed | What it is |
|---|---|
| Oct 7, 20264 | Insider transaction (Form 4) |
| Oct 5, 20263 | Initial insider holdings (Form 3) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 14, 20264 | Insider transaction (Form 4) |
| Sep 14, 2026144 | Notice of proposed sale (Form 144) |
| Sep 10, 2026144 | Notice of proposed sale (Form 144) |
| Sep 8, 20264 | Insider transaction (Form 4) |
| Sep 8, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 1, 2026144 | Notice of proposed sale (Form 144) |
| Aug 31, 20264 | Insider transaction (Form 4) |
| Aug 31, 20264 | Insider transaction (Form 4) |
| Aug 31, 20264 | Insider transaction (Form 4) |
| Aug 12, 2026SCHEDULE 13G | Other filings |
| Aug 7, 20264 | Insider transaction (Form 4) |
| Aug 6, 2026SCHEDULE 13G/A | Other filings |
| Aug 5, 2026144 | Notice of proposed sale (Form 144) |
| Jul 24, 2026SCHEDULE 13G/A | Other filings |
| Jul 16, 20264 | Insider transaction (Form 4) |
| Jul 15, 2026144 | Notice of proposed sale (Form 144) |
| Jul 10, 20264 | Insider transaction (Form 4) |
| Jul 10, 20263 | Initial insider holdings (Form 3) |
The newest 25 of 80 shown; the full year is on EDGAR.
2025 · 66 filings — 50 × 4, 5 × SC TO-C, 3 × 144 and 5 other forms
| Filed | What it is |
|---|---|
| Dec 16, 2025SC TO-I/A | Beneficial ownership |
| Dec 15, 20254 | Insider transaction (Form 4) |
| Dec 15, 20254 | Insider transaction (Form 4) |
| Dec 11, 2025144 | Notice of proposed sale (Form 144) |
| Dec 11, 20254 | Insider transaction (Form 4) |
| Dec 9, 2025144 | Notice of proposed sale (Form 144) |
| Dec 8, 20254 | Insider transaction (Form 4) |
| Dec 8, 20254 | Insider transaction (Form 4) |
| Dec 2, 20254 | Insider transaction (Form 4) |
| Dec 2, 20254 | Insider transaction (Form 4) |
| Dec 1, 20254 | Insider transaction (Form 4) |
| Dec 1, 20254 | Insider transaction (Form 4) |
| Dec 1, 20254 | Insider transaction (Form 4) |
| Nov 18, 2025SC TO-I/A | Beneficial ownership |
| Nov 13, 2025SC TO-I | Beneficial ownership |
| Nov 12, 2025SC TO-C | Beneficial ownership |
| Nov 6, 2025SC TO-C | Beneficial ownership |
| Nov 5, 2025SCHEDULE 13G/A | Other filings |
| Oct 21, 2025SC TO-C | Beneficial ownership |
| Oct 10, 2025SC TO-C | Beneficial ownership |
| Oct 6, 20254 | Insider transaction (Form 4) |
| Oct 6, 20254 | Insider transaction (Form 4) |
| Oct 3, 2025SC TO-C | Beneficial ownership |
| Sep 2, 20254 | Insider transaction (Form 4) |
| Sep 2, 20254 | Insider transaction (Form 4) |
The newest 25 of 66 shown; the full year is on EDGAR.
2024 · 163 filings — 84 × 4, 71 × 144, 5 × SC 13G/A and 2 other forms
| Filed | What it is |
|---|---|
| Dec 10, 20244 | Insider transaction (Form 4) |
| Dec 9, 2024144 | Notice of proposed sale (Form 144) |
| Dec 6, 20244 | Insider transaction (Form 4) |
| Dec 6, 20244 | Insider transaction (Form 4) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 3, 2024144 | Notice of proposed sale (Form 144) |
| Dec 3, 2024144 | Notice of proposed sale (Form 144) |
| Dec 2, 20244 | Insider transaction (Form 4) |
| Dec 2, 20244 | Insider transaction (Form 4) |
| Dec 2, 20244 | Insider transaction (Form 4) |
| Nov 29, 2024144 | Notice of proposed sale (Form 144) |
| Nov 29, 2024144 | Notice of proposed sale (Form 144) |
| Nov 29, 2024144 | Notice of proposed sale (Form 144) |
| Nov 12, 20244 | Insider transaction (Form 4) |
| Nov 12, 2024144 | Notice of proposed sale (Form 144) |
| Oct 8, 20244 | Insider transaction (Form 4) |
| Oct 7, 2024144 | Notice of proposed sale (Form 144) |
| Oct 4, 20244 | Insider transaction (Form 4) |
| Oct 4, 20243 | Initial insider holdings (Form 3) |
| Sep 10, 20244 | Insider transaction (Form 4) |
| Sep 9, 2024144 | Notice of proposed sale (Form 144) |
| Sep 4, 20244 | Insider transaction (Form 4) |
| Sep 4, 20244 | Insider transaction (Form 4) |
| Sep 3, 2024144 | Notice of proposed sale (Form 144) |
The newest 25 of 163 shown; the full year is on EDGAR.
2023 · 181 filings — 100 × 4, 72 × 144, 4 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2022 · 190 filings — 180 × 4, 4 × 3, 4 × SC 13G/A and 2 other forms
Counted, not listed; the year is on EDGAR.
2021 · 300 filings — 287 × 4, 5 × SC 13G/A, 4 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2020 · 249 filings — 222 × 4, 12 × 4/A, 3 × 3 and 6 other forms
Counted, not listed; the year is on EDGAR.
2019 · 38 filings — 32 × 4, 3 × SC 13G, 1 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2018 · 48 filings — 16 × 3, 9 × 4, 4 × CORRESP and 14 other forms
Counted, not listed; the year is on EDGAR.
2016 · 1 filing — 1 × D
Counted, not listed; the year is on EDGAR.
About this data#
Moderna Inc. (MRNA) has 1,493 filings on EDGAR going back to 2016: 9 annual reports, 23 quarterly reports and 117 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 20, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Sep 30, 2026, furnished a press release headed “Moderna Adds Chief Operating Officer Role as Company Expands into Oncology”. Over the last 13 months insiders sold $63.9M in 13 sales and bought nothing on the open market; 159 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Moderna Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read MRNA's latest 10-K?
- MRNA's latest annual report, a 10-K, was filed on Feb 20, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did MRNA last file an 8-K?
- On Sep 30, 2026 it furnished a press release headed “Moderna Adds Chief Operating Officer Role as Company Expands into Oncology”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 31, 2026.
- Are MRNA insiders buying or selling?
- Over the last 13 months insiders sold $63.9M in 13 sales and bought nothing on the open market; 159 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Hoge Stephen (President) sold 40,281 shares on Sep 15, 2026 for $5.9M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has MRNA made?
- 1,493 filings are on EDGAR under the registrant records that have been Moderna Inc., going back to 2016; 1,225 of them are insider ownership forms (Forms 3, 4, 5 and 144).